Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$0.88 USD

0.88
104,369

0.00 (0.34%)

Updated Apr 30, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates

Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

Amarin (AMRN) closed at $19.40 in the latest trading session, marking a +0.41% move from the prior day.

AstraZeneca to End Phase III Study on Fish Oil Heart Drug

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Applied Therapeutics Up on Positive Galactosemia Study Data

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Why Amarin (AMRN) Stock Might be a Great Pick

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.

Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher

Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.

aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $21.23, marking a +1.34% move from the previous day.

Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?

Is (AMRN) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) is a Great Momentum Stock: Should You Buy?

Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

Amarin Gains on FDA Approval of Vascepa Label Expansion

Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.

Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?

Is (AMRN) Outperforming Other Medical Stocks This Year?